Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: A multi-centre, randomized, single-blind comparison trial

Addiction

Volumn 105, Issue 2, 2010, Pages 288-299

  Martinotti, Giovanni ^a,b   Di Nicola, Marco ^b   Frustaci, Alessandra ^b   Romanelli, Roberto ^c   Tedeschi, Daniela ^b   Guglielmo, Riccardo ^b   Guerriero, Luigi ^b   Bruschi, Angelo ^b   De Filippis, Rocco ^b   Pozzi, Gino ^b   Di Giannantonio, Massimo ^d   Bria, Pietro ^b   Janiri, Luigi ^b  

^a Clinica Villa Maria Pia   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Casa di Cura 'Villa Silvia' ^*  (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Alcohol withdrawal; Benzodiazepines; CIWA Ar; Craving; Pregabalin; Tiapride

Indexed keywords

4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DRUG DERIVATIVE; LORAZEPAM; PREGABALIN; TIAPRIDE;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; ANALGESICS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SUBSTANCE WITHDRAWAL SYNDROME; TIAPRIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74249108901     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02792.x     Document Type: Article

References (84)

1. Hall W., Zador D. The alcohol withdrawal syndrome. Lancet 1997 349 : 1897 1900.
2. Kosten T. R., O'Connor P. G. Management of drug and alcohol withdrawal. N Engl J Med 2003 348 : 1786 1795.
3. Swift R. M. Drug therapy for alcohol dependence. N Engl J Med 1999 340 : 1482 1490.
4. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World 1998 22 : 13 24.
5. Addolorato G., Leggio L., Abenavoli L., Gasbarrini G., Alcoholism Treatment Study Group. Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav 2005 30 : 1209 1224. (Pubitemid 40745377)
6. Chastain G. Alcohol, neurotransmitter systems, and behavior. J Gen Psychol 2006 133 : 329 335.
7. Koob G. F. A role for GABA mechanisms in the motivational effects of alcohol. Biochem Pharmacol 2004 68 : 1515 1525.
8. Heinz A., Schmidt K., Baum S. S., Kuhn S., Dufeu P., Schmidt L. G. et al. Influence of dopaminergic transmission on severity of withdrawal syndrome in alcoholism. J Stud Alcohol 1996 57 : 471 474.
9. De Witte P., Pinto E., Ansseau M., Verbanck P. Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev 2003 27 : 189 197.
10. Swift R., Davidson D. Alcohol hangover: mechanisms and mediators. Alcohol Health Res World 1998 22 : 54 60.
11. Fiellin D. A., O'Connor P. G., Holmboe E. S., Horwitz R. I. Risk for delirium tremens in patients with alcohol withdrawal syndrome. Subst Abuse 2002 23 : 83 94.
12. Pieninkeroinen I. P., Telakivi T. M., Hillbom M. E. Outcome in subjects with alcohol-provoked seizures. Alcohol Clin Exp Res 1992 16 : 955 959.
13. Morton A. W., Laird L. K., Crane D. F., Partovi N., Frye L. H. A prediction model for identifying alcohol withdrawal seizures. Am J Drug Alcohol Abuse 1994 20 : 75 86.
14. Lerner W. D., Fallon H. J. The alcohol withdrawal syndrome. N Engl J Med 1985 313 : 951 952.
15. Schuckit M. A. Alcoholism acute treatment. In : Schuckit M. A., editor. Drug and Alcohol Abuse. A Clinical Guide to Diagnosis and Treatment, New York : Plenum Medical Book Co 1995, p. 97 117.
16. Vonghia L., Leggio L., Ferrulli A., Bertini M., Gasbarrini G., Addolorato G., Alcoholism Treatment Study Group. Acute alcohol intoxication. Eur J Intern Med 2008 19 : 561 567.
17. Finn D. A., Crabbe J. C. Exploring alcohol withdrawal syndrome. Alcohol Health Res World 1997 21 : 149 156.
18. Martinotti G., Di Nicola M., Reina D., Andreoli S., Focà F., Cunniff A. et al. Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse 2008 43 : 271 284.
19. Shaw J. M., Kolesar G. S., Sellers E. M., Kaplan H. L., Sandor P. Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. J Clin Psychopharmacol 1981 1 : 382 388.
20. Sullivan J. T., Sykora K., Schneiderman J., Naranjo C. A., Sellers E. M. Assessment of alcohol withdrawal: the revised clinical Institute Withdrawal Assessment for Alcohol scale (CIWA Ar). Br J Addict 1989 84 : 353 357.
21. Sullivan J. T., Swift R. M., Lewis D. C. Benzodiazepines requirements during alcohol withdrawal syndrome: clinical implications of using standardized withdrawal scale. J Clin Psychopharmacol 1991 11 : 291 295.
22. Lejoyeux M., Solomon J., Ades J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998 33 : 563 575.
23. O'Connor P. G., Schottenfeld R. S. Patients with alcohol problems. N Engl J Med 1998 338 : 592 502.
24. Nutt D., Adinoff B., Linnoila M. Benzodiazepines in the treatment of alcoholism. In : Galanter M., editor. Recent Development in Alcoholism. American Society of Addiction Medicine and Research Society on Alcoholism. New York : Plenum Press 1989, p. 283 313.
25. Saitz R., Mayo-Smith M. F., Roberts M. S., Redmond H. A., Bernard D. R. Calkins D. R. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA 1994 272 : 519 523.
26. Mayo-Smith M. F. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline: American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997 278 : 144 151.
27. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med 2005 352 : 596 607.
28. Morgan M. Y. The management of alcohol withdrawal using clomethiazole. Alcohol Alcohol 1995 30 : 771 774.
29. Williams D., McBride A. J. The drug treatment of alcohol withdrawal symptoms: a systematic review. Alcohol Alcohol 1998 33 : 103 115.
30. Holbrook A. M., Crowther R., Lotter A., Cheng C., King D. Diagnosis and management of acute alcohol withdrawal. Can Med Assoc J 1999 160 : 675 680.
31. Ross H. E. Benzodiazepine use and anxiolytic abuse and dependence in treated alcoholics. Addiction 1993 88 : 209 218.
32. Myrick H., Anton R., Voronin K., Wang W., Henderson S. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res 2007 31 : 221 227.
33. Jaffe J. H., Ciraulo D. A., Nies A., Dixon R. B., Monroe L. L. Abuse potential of lorazepram and diazepam in patients recently treated for acute alcohol withdrawal. Clin Pharmacol Ther 1983 34 : 623 630.
34. Ciraulo D. A., Sands B. F., Shader R. I. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry 1988 145 : 1501 1506.
35. Malcolm R. J. GABA systems, benzodiazepines, and substance dependence. J Clin Psychiatry 2003 64 : 36 40.
36. Poulos C. X. Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers. Behav Pharmacol 2004 15 : 503 512.
37. Ait-Daoud N., Malcolm R. J. Jr., Johnson B. A. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav 2006 31 : 1628 1649.
38. Maneuf Y. P., McKnight A. T. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001 134 : 237 240.
39. Dooley D. J., Donovan C. M., Pugsley T. A. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000 295 : 1086 1093.
40. Field M. J., Oles R. J., Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001 132 : 1 4.
41. Fink K., Dooley D. J., Meder W. P., Suman-Chauhan N., Duffy S., Clusmann H. et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002 42 : 229 236.
42. Feltner D. E., Crockatt J. G., Dubovsky S. J., Cohn C. K., Shrivastava R. K., Targum S. D. et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003 23 : 240 249.
43. Pande A. C., Crockatt J. G., Feltner D. E., Janney C. A., Smith W. T., Weisler R. et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003 160 : 533 540.
44. Pohl R. B., Feltner D. E., Fieve R. R., Pande A. C. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005 25 : 151 158.
45. Rickels K., Pollack M. H., Feltner D. E., Lydiard R. B., Zimbroff D. L., Bielski R. J. et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005 62 : 1022 1030.
46. Montgomery S. A. Pregabalin for the treatment of generalized anxiety disorder. Exp Opin Pharmacother 2006 7 : 2139 2154.
47. Martinotti G., Di Nicola M., Tedeschi D., Mazza M., Janiri L., Bria P. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008 25 : 608 618.
48. Martinotti G., Di Nicola M., Tedeschi D., Andreoli S., Reina D., Pomponi M. et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 2009 Epub ahead of print.
49. Scatton B., Cohen C., Perrault G., Oblin A., Claustre Y., Schoemaker H. et al. The preclinical pharmacologic profile of tiapride. Eur Psychiatry 2001 16 : 29s 34s.
50. Allain H., Dauzenberg P. H., Maurer K., Schuck S., Bonhomme D., Gerard D. Double blind study of tiapride versus haloperidol and placebo agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology 2000 148 : 361 366.
51. Peters D. H., Faulds D. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994 47 : 1010 1032.
52. Agricola R., Mazzarino M., Urani R. Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double blind comparison with tiapride. J Intern Med Res 1982 10 : 160 165.
53. Lepola U., Kokko S., Nuutila J., Gordin A. Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial. Int J Clin Pharmacol Res 1984 5 : 321 326.
54. Murphy D. J., Shaw G. K., Clarke I. Tiapride and chlormethiazole in alcohol withdrawal: a double-blind trial. Alcohol Alcohol 1983 18 : 227 237.
55. Jonasch K., Mende M. Treatment of alcohol withdrawal with tiapride (TiapridexR) vs. clomethiazol (DistraneurinR). An open-label trial. Krankenhauspsychiatrie 2004 15 : 114 116 in German M., Morhart-Klute V., Horak M. A combination of carbamazepine/tiapride in outpatient alcohol detoxification - results from an open clinical study. Eur Arch Psychiatry Clin Neurosci 2002 252 : 197 200.
56. Soyka M., Schmidt P., Franz M., Barth T., De Groot M., Kienast T. et al. Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci 2006 256 : 395 401.
57. Gartenmeier A., Pelzer E., Soyka M. Treatment of alcohol withdrawal syndrome with combined carbamazepine and tiapride in a patient with probable sleep apnoe syndrome. Pharmacopsychiatry 2005 3 : 96 8.
58. Franz M., Dlabal H., Kunz S., Ulferts J., Gruppe H., Gallhofer B. Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study. Eur Arch Psychiatry Clin Neurosci 2001 251 : 185 192.
59. First M. B., Spitzer R. L., Gibbon M., Williams B.W., Benjamin L. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). New York : Biometrics Research Department, New York State Psychiatric Institute 1990.
60. First M. B., Spitzer R. L., Gibbon M., Williams J. B. Structured Interview for DSM-IV Axis I Disorders - Patient Edition (SCID - I/P, version 2.0). New York : Biometrics Research Department, New York State Psychiatric Institute 1995.
61. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC : American Psychiatric Association 2000.
62. Mottola C. A. Measurement strategies: the visual analogue scale. Decubitus 1993 6 : 56 8.
63. Krupitsky E., Rudenko A., Burakov A., Slavina T., Grinenko A., Pittman B. et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007 31 : 604 611.
64. Janiri L., Calvosa F., Dario T., Pozzi G., Ruggeri A., Addolorato G. et al. The Italian version of the Obsessive-Compulsive Drinking Scale: validation, comparison with the other versions, and difference between type 1- and type 2-like alcoholics. Drug Alcohol Depend 2004 74 : 187 195.
65. Derogatis L. R., Lipman R. S., Covi L. SCL-90: an outpatient psychiatric rating scale: preliminary report. In : Guy W., editor. ECDEU Assessment Manual for Psychopharmacology. 1976 revision. DHEW publication no. (ADM). Rockville, MD : National Institute for Mental Health 1976, p. 76 338.
66. Spitzer W. O., Dobson A. J., Hall J. Chesterman E., Levi J., Shepherd R., Battista R. N. et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981 34 : 585 597.
67. Chick J. Delirium tremens. BMJ 1989 298 : 3 4.
68. Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry 2008 32 : 1106 1117.
69. Beydoun A., Nasreddine W., Atweh S. Efficacy and tolerability of pregabalin in partial epilepsy. Exp Rev Neurother 2008 8 : 1013 1024.
70. Fontaine R., Chouinard G., Annable L. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 1984 141 : 848 852.
71. Rickels K., Fox I. L., Greenblatt D. J., Sandler K. R., Schless A. Clorazepate and lorazepam: clinical improvement and rebound anxiety. Am J Psychiatry 1988 145 : 312 317.
72. Steele J. W., Faulds D., Sorkin E. M. Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation. Drugs Aging 1993 3 : 460 478.
73. Roger M., Gerard D., Leger J. M. Value of tiapride for agitation in the elderly. Review of published studies. Encephale 1998 24 : 462 468.
74. Dose M., Lange H. W. The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes. Pharmacopsychiatry 2000 33 : 19 27.
75. Jiménez-Jiménez F. J., García-Ruiz P. J. Pharmacological options for the treatment of Tourette's disorder. Drugs 2001 61 : 2207 2220.
76. Robert P. H., Allain H. Clinical management of agitation in the elderly with tiapride. Eur Psychiatry 2001 16 : 42s 7s.
77. Rosenstock J., Tuchman M., LaMoreaux L., Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: double-blind, placebo-controlled trial. Pain 2004 110 : 628 638. (Pubitemid 39036794)
78. Christensen A. F., Poulsen J., Nielsen C. T., Bork B., Christensen A., Christensen M. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand 2006 113 : 148 153.
79. Montgomery S. A., Tobias K., Zornberg G. L., Kasper S., Pande A. C. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006 67 : 771 782.
80. Appleton R., Macleod S., Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2008 3 CD001905.
81. Morgan P. T., Malison R. T. Pilot study of lorazepam and tiagabine effects on sleep, motor learning, and impulsivity in cocaine abstinence. Am J Drug Alcohol Abuse 2008 34 : 692 702.
82. Muchohi S. N., Obiero K., Newton C. R., Ogutu B. R., Edwards G., Kokwaro G. O. Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. Br J Clin Pharmacol 2008 65 : 12 21.
83. Huang T. L., Hung Y. Y. Lorazepam reduces the serum brain-derived neurotrophic factor level in schizophrenia patients with catatonia. Prog Neuropsychopharmacol Biol Psychiatry 2009 33 : 158 159.
84. Sreenath T.G., Gupta P., Sharma K. K., Krishnamurthy S. Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. Eur J Paediatr Neurol 2009 Epub ahead of print.